| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 196.7 | 158.3 | 162.7 |
| Other income | 6.0 | 5.4 | 10.2 |
| Total income | 202.7 | 163.7 | 172.8 |
| Profit before exceptional items & tax | 71.0 | 54.3 | 59.5 |
| Profit before tax | 71.0 | 54.3 | 59.5 |
| Net profit | 51.8 | 40.6 | 46.8 |
| Operating margin | 35.0% | 33.2% | 34.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +10.70% |
|---|---|
| Net profit, quarter on quarter | +27.60% |
| Revenue, year on year | +20.90% |
| Operating profit, year on year | +31.80% |
| Operating profit, quarter on quarter | +32.90% |
BSE results filing, NSE: SUDEEPPHRM. Figures extracted from the filing.
Sudeep Pharma Ltd: key numbers
- Share price
- ₹1,130.10
- Market cap
- ₹12,764 Cr
- Revenue (annual)
- ₹642.3 Cr
- Net profit (annual)
- ₹172.9 Cr
- P/E (TTM)
- 67.8×Sector 48.7×
- Promoter holding
- 76.15%+0.00% QoQ
- FII holding
- 2.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sudeep Pharma Ltd
All →Sudeep Pharma Earnings Call Transcript: Key Takeaways
Sudeep Pharma delivered record quarterly revenue led by its Pharma Food Nutrition (PFN) segment, though specialty ingredients face short-term headwinds from the pause of a government rice program.
Sudeep Pharma Investor Presentation: Key Takeaways
Q2FY27 revenue Rs196.7cr (+21% YoY), record EBITDA Rs73.2cr (+32%, 37.2% margin), PAT Rs51.8cr (+11%). Battery-materials pivot and Nandesari FDA approval are the strategic highlights.
Sudeep Pharma Capacity Expansion
Sudeep Pharma received FDA approval for its new 51,200 MT greenfield plant at Nandesari, Gujarat. Commercial operations are expected to commence in H2 FY27 following customer qualification.
- manufacturing capacity
- 51200 MT
Sudeep Pharma Board Meeting Date
Sudeep Pharma has scheduled its Board meeting for 28 October 2026 to approve Q1 and H1 FY27 financial results. No results or monetary figures are disclosed in this intimation.
Sudeep Pharma Other Announcement
The company submitted the mandatory compliance certificate under Regulation 74(5) for the quarter ended September 30, 2026.
Sudeep Pharma Management Change
Mr. Sendhil Pani has ceased to be a Senior Management Personnel of Sudeep Pharma Ltd effective October 2, 2026. This follows the completion of his contractual arrangements.